154 related articles for article (PubMed ID: 26871478)
1. Mutanome and expression of immune response genes in microsatellite stable colon cancer.
Sanz-Pamplona R; Gil-Hoyos R; López-Doriga A; Alonso MH; Aussó S; Molleví DG; Santos C; Sanjuán X; Salazar R; Alemany R; Moreno V
Oncotarget; 2016 Apr; 7(14):17711-25. PubMed ID: 26871478
[TBL] [Abstract][Full Text] [Related]
2. Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma.
Matsushita H; Sato Y; Karasaki T; Nakagawa T; Kume H; Ogawa S; Homma Y; Kakimi K
Cancer Immunol Res; 2016 May; 4(5):463-71. PubMed ID: 26980598
[TBL] [Abstract][Full Text] [Related]
3. HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression.
Dierssen JW; de Miranda NF; Ferrone S; van Puijenbroek M; Cornelisse CJ; Fleuren GJ; van Wezel T; Morreau H
BMC Cancer; 2007 Feb; 7():33. PubMed ID: 17316446
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
5. High expression of AT-rich interactive domain 3A (ARID3A) is associated with good prognosis in colorectal carcinoma.
Song M; Kim H; Kim WK; Hong SP; Lee C; Kim H
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S481-9. PubMed ID: 24366420
[TBL] [Abstract][Full Text] [Related]
6. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy.
Xiao Y; Freeman GJ
Cancer Discov; 2015 Jan; 5(1):16-8. PubMed ID: 25583798
[TBL] [Abstract][Full Text] [Related]
7. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
8. Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer.
Nitsche U; Rosenberg R; Balmert A; Schuster T; Slotta-Huspenina J; Herrmann P; Bader FG; Friess H; Schlag PM; Stein U; Janssen KP
Ann Surg; 2012 Nov; 256(5):763-71; discussion 771. PubMed ID: 23095620
[TBL] [Abstract][Full Text] [Related]
9. The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer.
Hong SP; Min BS; Kim TI; Cheon JH; Kim NK; Kim H; Kim WH
Eur J Cancer; 2012 May; 48(8):1235-43. PubMed ID: 22071131
[TBL] [Abstract][Full Text] [Related]
10. Telomere length alterations in microsatellite stable colorectal cancer and association with the immune response.
Lopez-Doriga A; Valle L; Alonso MH; Aussó S; Closa A; Sanjuan X; Barquero D; Rodríguez-Moranta F; Sanz-Pamplona R; Moreno V
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):2992-3000. PubMed ID: 29908233
[TBL] [Abstract][Full Text] [Related]
11. 1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer.
Mayrhofer M; Kultima HG; Birgisson H; Sundström M; Mathot L; Edlund K; Viklund B; Sjöblom T; Botling J; Micke P; Påhlman L; Glimelius B; Isaksson A
BMC Cancer; 2014 Nov; 14():872. PubMed ID: 25420937
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability.
Ishikawa T; Fujita T; Suzuki Y; Okabe S; Yuasa Y; Iwai T; Kawakami Y
Cancer Res; 2003 Sep; 63(17):5564-72. PubMed ID: 14500396
[TBL] [Abstract][Full Text] [Related]
13. High SMAD4 levels appear in microsatellite instability and hypermethylated colon cancers, and indicate a better prognosis.
Isaksson-Mettävainio M; Palmqvist R; Dahlin AM; Van Guelpen B; Rutegård J; Oberg A; Henriksson ML
Int J Cancer; 2012 Aug; 131(4):779-88. PubMed ID: 21964812
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level.
Samowitz WS; Curtin K; Ma KN; Schaffer D; Coleman LW; Leppert M; Slattery ML
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):917-23. PubMed ID: 11535541
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer.
Manceau G; Marisa L; Boige V; Duval A; Gaub MP; Milano G; Selves J; Olschwang S; Jooste V; le Legrain M; Lecorre D; Guenot D; Etienne-Grimaldi MC; Kirzin S; Martin L; Lepage C; Bouvier AM; Laurent-Puig P
Cancer Med; 2015 Mar; 4(3):371-82. PubMed ID: 25641861
[TBL] [Abstract][Full Text] [Related]
16. Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy.
Turksma AW; Coupé VM; Shamier MC; Lam KL; de Weger VA; Belien JA; van den Eertwegh AJ; Meijer GA; Meijer CJ; Hooijberg E
Clin Cancer Res; 2016 Jan; 22(2):346-56. PubMed ID: 26420855
[TBL] [Abstract][Full Text] [Related]
17. Expression of apoptosis regulating proteins identifies stage II and III colon cancer patients with high risk of recurrence.
Belt EJ; Stockmann HB; Delis-van Diemen PM; Bril H; Tijssen M; van Essen HF; Heymans MW; Beliën JA; Carvalho B; Cillessen SA; Meijer GA
J Surg Oncol; 2014 Mar; 109(3):255-65. PubMed ID: 24249458
[TBL] [Abstract][Full Text] [Related]
18. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer.
de Weger VA; Turksma AW; Voorham QJ; Euler Z; Bril H; van den Eertwegh AJ; Bloemena E; Pinedo HM; Vermorken JB; van Tinteren H; Meijer GA; Hooijberg E
Clin Cancer Res; 2012 Feb; 18(3):882-9. PubMed ID: 22156611
[TBL] [Abstract][Full Text] [Related]
19. Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis.
Løvig T; Andersen SN; Thorstensen L; Diep CB; Meling GI; Lothe RA; Rognum TO
Br J Cancer; 2002 Sep; 87(7):756-62. PubMed ID: 12232760
[TBL] [Abstract][Full Text] [Related]
20. Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas.
Kalady MF; Sanchez JA; Manilich E; Hammel J; Casey G; Church JM
Dis Colon Rectum; 2009 Jun; 52(6):1039-45. PubMed ID: 19581844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
